Keyword: Regeneron Pharmaceuticals
The eye drug star has nabbed an FDA nod as a 12-week formulation in wet AMD and is expected to get into diabetic retinopathy next May.
While the administration wants to attack "global freeloading" and reduce U.S. prices, some companies are set to feel the pain more than others.
Roche and Novartis are working hard on AMD drugs they hope can capture significant market share. Analysts, though, remain unconvinced.
Regeneron has received a complete response letter tied to manufacturing of a syringe as it shoots for another indication for blockbuster Eylea.
It's common for drugmakers to offer behind-the-scenes rebates to win coverage for their drugs. But Amgen's big retail price cut is a rare move.
Big biopharma CEOs gave most or all their campaign contributions to Republicans this season, but one went full blue with his $120,000.
Strong data for Dupixent in sinusitis could boost sales for Sanofi and Regeneron, but challenges abound, including payer pushback.
Sanofi and Regeneron's Libtayo may be the sixth in its class to launch, but it already has something not all its rivals do: a market all to itself.
Xolair, Nucala, Cinqair, Fasenra and Dupixent will need to take a 50% to 68% discount off the list price to achieve cost-effectiveness, says ICER.